PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Alirocumab - Lipid modification
PAD Profile : Alirocumab - Lipid modification
Keywords :
Hyperlipidaemia, PCSK9 inhibitor, lipid regulating, mixed dyslipidaemia, Primary hypercholesterolaemia, lipid-lowering, lipid lowering, raised cholesterol, high cholesterol
Brand Names Include :
Praluent
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid
- Inclisiran
- Icosapent
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
02 December 2021
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The APC recommends both presentations of alirocumab: 150mg fortnightly (see previous recommendation) AND 300mg monthly (new recommendation).
The monthly 300mg presentation maybe more conveniant for patients. It was not covered in the evidence base underpinning NICE TA393 but the PAS price is the same monthly cost as 150mg fortnightly.
Prescribing of either product should be in line with NICE TA393 under the conditions agreed in October 2016
05 October 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA393 (June 2016)
Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database. Alirocumab will be considered RED on the traffic light system
Associated BNF Codes
02. Cardiovascular System
02.12.00. Lipid-regulating drugs